Invest in Lupus Research
Organised by It has been an exciting year for the lupus community with the approval of three treatments for lupus. Help us keep the momentum going.
Story
When it comes to lupus treatment news, 2021 was a year of tremendous progress! Because of the complexity of lupus, drug research and development can be especially challenging. But this past year, decades of hard work led to three new drugs receiving FDA-approval for the treatment of lupus and lupus nephritis: Belimumab (Benlysta), Voclosporin (Lupkynis), and Aanifrolumab (Saphnelo).
The Lupus Foundation of America, Heartland Chapter is proud to play a role in the advancement of lupus treatment development and care, from providing research funding to working tirelessly to find ways to improve trial design, including working with the FDA to create a path forward for treatment development. We have also educated people with lupus and connected them to important clinical trial information
There is an undeniable surge in research momentum, and the lupus community is feeling the excitement. We have never before had a year of such progress in lupus. With support from the Lupus Foundation of America, patients, donors, academic researchers, clinicians, and the pharmaceutical industry, the pace of discovery is accelerating and the wait for new treatments is anticipated to be much shorter. - Alfred Kim, MD, PhD, Co-Director of the Lupus Clinic at Washington University
Our donors helped to make this progress possible with their generous financial support. Please help continue this momentum by making a donation today to invest in lupus research, educate people with lupus, and connect them to important clinical trial information.